Our pipeline includes Tissue-Specific Therapeutics and Tissue-Specific Biologics for soft tissue sarcoma, colorectal cancer, and inflammatory bowel disease. We believe our oncology drug candidates
will replace first-line therapies across a multitude of cancer indications. Next planned clinical trial is a Phase 2a proof-of-concept first-line-therapy study of IMX-110 as a monotherapy in soft tissue sarcoma.
Our Clinical Trials
Our lead candidate IMX-110, a potential first-line therapy for soft tissue sarcoma, is currently in clinical trials as a monotherapy, and is planned to be combined with tislelizumab (BeiGene anti-PD-1) for advanced solid tumors. IMX-111 and IMX-120 clinical trials are planned in oncology and immuno-dysregulated diseases, respectively.
Historical/Ongoing Clinical Trials
– IMX-110 Phase 1b/2a Trial: IMX-110 in Patients With Advanced Solid Tumors
Scientific Posters, Publications & Reviews
IMX-110 Mechanism of Action